Oral xenogenic immunomodulating peptide – transfer factor

Czech version

Authors: J. Richter ¹; V. Větvička ²
Authors‘ workplace: Zdravotní ústav se sídlem v Ústí nad Labem Centrum imunologie a mikrobiologie Vedoucí: Ing. Eduard Ježo ¹; University of Louisville, KY, USA Department of Pathology and Laboratory Medicine Vedoucí: Eyas M. Hattab, MD, MBA ²
Published in: Prakt. Lék. 2023; 103(6): 304-308
Category: Of different specialties

Overview

Transfer factor (TF) was described in 1955 by S. Lawrence. In 1976, as part of a WHO scholarship, contact was made with C.H. Kirkpatrick, who provided us with the preparation methodology. Kirkpatrick in 1992 characterized the specific transfer factor at the molecular level. Thanks to him, in 1967, at our workplace, xenogenic transfer factor from pig bloodwas prepared in the application form of oral administration. The transfer factor was gradually introduced as part of theresearch not only in clinical practice, but also in preventive application in individuals with a significant burden on theimmune system due to various factors, including physical stress, post-infection insufficiency of the immune system or inpatients after radiation and chemotherapy treatment of cancer. We verified new approaches to the definition of TF andbroadening the spectrum of induction of post-application changes in a group of elite athletes, hockey representatives,where we confirmed the reported changes in immunoglobulin values, but we also found other significant changes, especially in the spectrum of proteins affecting the metabolism of iron and other minerals. In the last period ofapplication in the post-COVID-19 syndrome, we found a significant benefit of TF application for the rehabilitation of thepatient and his problems, where the possibility of applying the specific component of the SARS Co V-2 virus, which infects pig farms, can be assumed. The findings point to the necessity of further monitoring of the issue of TF, which could be beneficial for a detailed definition of this food supplement.

Keywords:

prevention – xenogenic transfer factor – oral application – clinic

Sources

Berrón-Pérez R, Cháves-Sánchez R, Estrada-Garcia I, et al. Indications, usage and dosage of the transfer factor. Rev Alerg Mex 2007; 54(4): 134–139.
Bonilla DA, Moreno Y, Petro JL, et al. A bioinformatics-assisted review on iron metabolism and immune system to identify potentialbiomarkers of exercise stress-induced immunosuppression. Biomedicines 2022; 10(3): 724.
Buc M, Siska P, Rovenský J, et al. Zmeny T-lymfocytárnej odpovede po posobeni transfer faktora in vivo. Bratisl Lek listy 1982; 78: 64–74.
Castrejón Vázquez MI, Reséndiz-Albor AA, Ynga-Durand MA, et al. Dialysable leucocyte extract (Transferontm) administration in sepsis:experience from a single referral pediatric intensive care unit. Biomed Res Int 2019; 2019: 8980506.
deVinci C, Levine PH, Pizza G, et al. Lessons from a pilot study of transfer factor in chronic fatigue syndrome. Biotherapy 1996; 9(1–3):87–90.
Hennen WJ. Enhanced Transfer Factor [online]. Dostupné z: http:// www.discovertransferfactor.com/transferfactorebook(enhanced). pdf [cit. 2023-12-15].
Hrčková G, Mačak Kubašková T, Mudruňová D, et al. Cotreatment with human leucocyte and albendazole stimulates drug’s efficacyand Th1 biased immune response in Mesocestoides vogae (Cestoda) infection via modulation of transcription factors, macrophagepolarization, and cytokine profiles. Pharmaceutics 2023; 15(2): 541.
Kempová V, Zaťavičová M, Kajanová L, et al. Obstacles and limitations of transfer factor biological aktivity assay design. Acta Virol 2020; 64(3): 271–475.
Kirkpatrick CH. Transfer factors: identification of conserved sequences in transfer factor molecules. Mol Med 2000; 6(4): 332–341.
Kirkpatrick CH. Activities and characteristics of transfer factors. Biotherapy 1996; 9(1–3): 13–16.
Kirkpatrick CH, Ottenson EA, Smith TK, et al. Reconstitution of defective cellular immunity with foetal thymus and dialysable transferfactor. Long-term studies in a patient with chronic mucocutaneous candidiasis. Clin Exp Immunol 1976; 23(3): 414–428.
Kvasnička J, Richter J, Pekárek J, et al. Transfer faktor. Čas. Lék. čes. 1980; 119: 1427–1430.
Krishnaveni M. A review on transfer factor an immune modulator. JPR Solutions 2013; 5(2): 153–156.
Lawrence HS. Transfer factor in cellular immunity. Harvey Lect 1974; 68: 239-350.
Lawrence HS. The cellular transfer of cutaneous hypersenstivity to tuberculin in man. Proc Soc Exp Biol Med 1949; 71(4): 516–522.
Mellado-Sanchez G, Lázaro-Rodriguez JJ, Avila S, et al. Development of functional directed to human dialyzable leucocyte extract (Transferon). J Immunology Re. 2019; 2019: 2754920.
Polonini H, de Souza Schmidt Goncalves AE, Dijkers E, et al. Characterization and safety profile of transfer factors peptides, a nutritional supplement for immune system regulation. Biomolecule. 2021; 11(5): 665.
Reyes-Ruiz A, Calvillo-Rodriguez M, Martinez-Torres AC. The bovine dialysable leucocyte extract IMMUNEPOTENT CRP induce immunogenic cell death in brest cancer cells leading to long-term antitumor memory. Brit J Cancer 2021; 124(8): 1398–1410.
Richter J. Our practical experiences with IMMUNOR. Klin Imunol Alergol 2003; 13(4): 34–36.
Rozzo SJ, Kirkpatrick CH. Purification of transfer factors. Mol Immunol 1992; 29(2): 167–182.
Salazar-Ramiro A, Hernández-Pedro NY, Ranger-Lopez E, et al. Dialysable leucocyte extract (transfer factor) as adjuvant immunotherapy inthe treatment of cancer. MOJ Immunol 2018; 6: 226–232.
Spitler LE. Clinical uses of transfer factor. Calif Med 1973; 118(2): 47.
Thakor JC, Dinoesh M, Manikandan R, et al. Swine coronaviruses (SCoVs) and their emerging threats to swine population, inter-speciestransmission, exploring the susceptibility of pigs for SARS-CoV-2 and zoonotic concerns. Vet Q 2023; 42(1): 125–147.
Trefný O, Richter J., Wünsch L. Možnosti využití imunologických vyšetřovacích metod pro sledování zdravotního stavu vrcholových sportovců-hokejistů. Teor Praxe Těl Vých 1986; 34: 103–106.
Tulina D, Chan MKS, WBF M, et al. Transfer factors or dialyzable leucocyte extracts as immunomodulating peptides: a conceptual review on broad spectrum of therapeutic areas, immunologic and clinical responses, trends and perspectives. Int J Immunol Immunother 2019; 6(1): 1–6.
Vallejo-Castillo L, Favari L, Vázquez-Leyva S, et al. Sequencing analysis and identification of the primary peptide component of the dialyzable leucocyte extract „Transferon Oral“: the starting point to understand its mechanism of action. Front Pharmacol 2020; 11: 569039.
Vetvicka V, Fernandez-Botran R. Non-specific immunostimulatory effects of transfer factor. Int Clin Pathol J 2020; 8(1): 1–6.
Viza D, Fudenberg HH, Palareti A, et al. Transfer factor: an overlooked potential for the prevention and treatment of infectious diseases. Folia Biol 2013; 59(2): 53–67.
White A. Research on transfer factors in disease treatment and prevention. Explore 2009; 18: 19–22.
Zhou X. Effect of adjuvant therapy of transfer factor oral solution on the infection proces of children with Mycoplasma pneumonia. J Hainan Medical University 2018; 24: 58–61.

adresa pro korespondenci:
MUDr. Josef Richter, CSc.
Zdravotní ústav se sídlem v Ústí nad Labem
Centrum imunologie a mikrobiologie
Na Kabátě 229, 400 11 Ústí nad Labem
e-mail: imuno.alergo@zuusti.cz

Labels

General practitioner for children and adolescents General practitioner for adults

Manifestations of blistering diseases in the oral cavity

The analysis of the relationship between dementia and atherosclerosis risk factors

Topical application of a medicinal preparation with β-glucan

Changes in metallothionein levels in patients with malignant prostate cancer – a pilot study

Intoxication by Cherry Laurel

Intoxication from Wall germander (Teucrium chamaedrys) after consuming a tea after recommendation from herbalist – risks of phytotherapy

Co zvyšuje riziko vzniku psychotického onemocnění po zneužívání kanabis

Article was published in

General Practitioner

2023 Issue 6